ITI in the era of emicizumab: paper published in Haemophilia
ITI in the era of emicizumab: paper published in Haemophilia
Dr. Katharina Holstein, Prof. Jan Astermark, Prof. Victor Jiménez-Yuste, Prof. Pål Andrè Holme, Prof. Angelika Batorova, Assoc. Prof. Sandra Le Quellec, Assoc. Prof. Robert Klamroth
The HEMOSTASIS CONNECT European Collaborative Haemophilia Network (ECHN) Group is proud to announce the publication of the paper: Immune tolerance induction in the era of emicizumab - still the first choice for patients with haemophilia A and inhibitors?
Dr. Katharina Holstein
Haematologist
Univeristy Medical Center Hamburg-Eppendorf (UKE)
Germany
Prof. Jan Astermark
Haematologist
Lund University and Skån University Hospital
Sweden
Prof. Victor Jiménez-Yuste
Haematologist
La Paz University Hospital
Spain
Prof. Pål Andrè Holme
Haematologist
Oslo University Hospital
Norway
Prof. Angelika Batorova
Haematologist
University Hospital Bratislava
Slovakia
Assoc. Prof. Sandra Le Quellec
Haematologist
France
Assoc. Prof. Robert Klamroth
Haematologist
Vivantes Hospital Friedrichshain
Germany
Now Published | 
60 min
download resources
I agree that this educational programme:
Was valuable to me:
1/3
The development of inhibitors to factor VIII (FVIII) is a serious complication of clotting factor replacement therapy associated with increased morbidity and mortality. According to guidelines patients with inhibitors should have access to immune tolerance induction (ITI) for eradication of inhibitors and to suitable haemostatic agents at specialized centres.
The European Collaborative Haemophilia Network (ECHN) conducted a survey on the use of ITI in Europe. Results have recently been published in the journal Haemophilia.
Access the publication and download the summary slide kit.
Dr. Holstein will be hosting a webinar on ITI on Wednesday June 1st as part of the National Hemophilia Foundation Wednesday Webinar series.
Other programmes of interest
60 min
